BUZZ-Oncolytics Biotech jumps after pancreatic cancer therapy gets regulatory nod
ReutersJan 15, 2025 1:05 PM
** U.S.-listed shares of Oncolytics Biotech ONC.TO, ONCY.O rise 35.8% to $1.10 premarket
** ONCY says its pancreatic cancer therapy, pelareorep, has received regulatory approval to continue patient enrollment
** ONCY is evaluating pelareorep in combination with chemotherapy regimen Folfirinox and immunotherapy atezolizumab
** ONCY says it will move forward with full enrollment of 30 newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients in the first stage
** All 5 brokerages covering the stock rate it "buy"
** ONCY fell ~31% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Related Articles
TSMC Delivers Record High Q4 2024 Profit: Shares Rise 4%
TradingKey - For semiconductor companies, there’s a lot of expectation heading into the latest earnings season as the Artificial Intelligence (AI) hype continues.TradingKey
9 hours ago
Can Earnings Season Be the Catalyst for U.S. Stocks?
TradingKey - Fears of persistent inflation, driven by strong employment data and Trump’s potential policies, have raised concerns that the Federal Reserve may scale back planned rate cuts. Combined with worries over high valuations and a potential stock market bubble, these factors have increased seTradingKey
Wed, Jan 15
What Impact Will California Wildfires Have on The Stock Market?
TradingKey - Right now in the US, there are ferocious wildfires that are destroying acres of both land and homes in California. Being spread by strong winds, the fires are also heading towards major urban centres, like Los Angeles.TradingKey
Fri, Jan 10
